Pharmaceutical Industry Enthusiastic About Cancer Drug Alliances and Bispecific Antibodies

Merck and Daiichi Sankyo strike a cancer drug alliance worth up to $22 billion, highlighting the pharmaceutical industry's enthusiasm for antibody-drug conjugates (ADCs). EpimAb Biotherapeutics and Almirall announce a license agreement to develop bispecific antibodies. I-Mab and ABL Bio provide updates on their PD-L1 and 4-1BB bispecific antibody TJ-L14B/ABL503. PharmaEssentia enters into a license agreement with Wuxi Biologics for a myeloid immune checkpoint antibody candidate. Ono Pharmaceutical enters into a drug discovery collaboration with Adimab to discover and develop novel antibody drugs in the oncology field.